Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Reducing fracture risk in men on androgen deprivation therapy

Nature Reviews Urology volume 8, pages 9–10 (2011)Cite this article

Subjects

Androgen deprivation therapy (ADT) is well established as a cause of osteoporosis and increased fracture risk. A study has shown that toremifene reduces fracture risk in men receiving ADT for prostate cancer. The study has substantial limitations, however, and the management of bone disease in these patients remains a challenge.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gilbert, S. M., Kuo, Y. F. & Shahinian, V. B. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. Urol. Oncol. doi: 10.1016/j.urolonc.2009.09.004.

  2. Shahinian, V. B., Kuo, Y. F., Freeman, J. L. & Goodwin, J. S. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154–164 (2005).

    Article  CAS  Google Scholar 

  3. Greenspan, S. L., Nelson, J. B., Trump, D. L. & Resnick, N. M. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann. Intern. Med. 146, 416–424 (2007).

    Article  Google Scholar 

  4. Smith, M. R. et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol. 169, 2008–2012 (2003).

    Article  CAS  Google Scholar 

  5. Smith, M. R. et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J. Urol. 184, 1316–1321 (2010).

    Article  CAS  Google Scholar 

  6. Keating, N. L., O'Malley, A. J. & Smith, M. R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24, 4448–4456 (2006).

    Article  CAS  Google Scholar 

  7. Grady, D. et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet. Gynecol. 104, 837–844 (2004).

    Article  CAS  Google Scholar 

  8. Smith, M. R. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361, 745–755 (2009).

    Article  CAS  Google Scholar 

  9. Buchan, N. C. & Goldenberg, S. L. Intermittent androgen suppression for prostate cancer. Nat. Rev. Urol. 7, 552–560 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Michigan, 102 Observatory Road, 208 Simpson Memorial Institute, Ann Arbor, 48109-0725, MI, USA

    Vahakn B. Shahinian

Authors
  1. Vahakn B. Shahinian
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares that he acts as a consultant for Amgen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shahinian, V. Reducing fracture risk in men on androgen deprivation therapy. Nat Rev Urol 8, 9–10 (2011). https://doi.org/10.1038/nrurol.2010.210

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2010.210

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing